FDA scheduled Alzheimer’s drug coverage meeting with payers before aducanumab approval
FDA has commissioned Duke-Margolis Center to organize a private roundtable meeting in July with payers and other stakeholders to discuss challenges associated with covering and developing evidence for Alzheimer’s therapies such as aducanumab from Biogen and Eisai.
Payers were invited to the roundtable in the spring, before Aduhelm aducanumab’s approval. BioCentury spoke with three invited participants who did not want to be identified because the meeting is private. One